Jan Soupal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/498167/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Novel biochemical markers for non-invasive detection of pancreatic cancer. Neoplasma, 2022, 69, 474-483.	0.7	5
2	Skin autofluorescence corresponds to microvascular reactivity in diabetes mellitus. Journal of Diabetes and Its Complications, 2022, 36, 108206.	1.2	2
3	Preâ€school and schoolâ€aged children benefit from the switch from a sensorâ€augmented pump to an <scp>AndroidAPS</scp> hybrid closed loop: A retrospective analysis. Pediatric Diabetes, 2021, 22, 594-604.	1.2	33
4	Response to Comment on HÃiskovÃi et al. Real-time CGM Is Superior to Flash Glucose Monitoring for Glucose Control in Type 1 Diabetes: The CORRIDA Randomized Controlled Trial. Diabetes Care 2020;43:2744–2750. Diabetes Care, 2021, 44, e77-e78.	4.3	1
5	Hybrid Closed-Loop Systems for the Treatment of TypeÂ1 Diabetes: A Collaborative, Expert Group Position Statement for Clinical Use in Central and Eastern Europe. Diabetes Therapy, 2021, 12, 3107-3135.	1.2	16
6	Glycemic Outcomes in Adults With T1D Are Impacted More by Continuous Glucose Monitoring Than by Insulin Delivery Method: 3 Years of Follow-Up From the COMISAIR Study. Diabetes Care, 2020, 43, 37-43.	4.3	168
7	Real-time CGM Is Superior to Flash Glucose Monitoring for Glucose Control in Type 1 Diabetes: The CORRIDA Randomized Controlled Trial. Diabetes Care, 2020, 43, 2744-2750.	4.3	83
8	Response to Comment on Åoupal et al. Glycemic Outcomes in Adults With T1D Are Impacted More by Continuous Glucose Monitoring Than by Insulin Delivery Method: 3 Years of Follow-up From the COMISAIR Study. Diabetes Care 2020;43:37–43. Diabetes Care, 2020, 43, e54-e55.	4.3	2
9	Lipid peroxidation and impaired vascular function in patients with type 1 diabetes mellitus. Monatshefte Für Chemie, 2019, 150, 525-529.	0.9	2
10	Postprandial microvascular reactivity is significantly modified by endogenous insulin in recently diagnosed Type 2 diabetic patients. Diabetes Research and Clinical Practice, 2018, 139, 300-307.	1.1	2
11	Excellent Glycemic Control Maintained by Open-Source Hybrid Closed-Loop AndroidAPS During and After Sustained Physical Activity. Diabetes Technology and Therapeutics, 2018, 20, 744-750.	2.4	62
12	Glycemic sensors in treatment of diabetes. Praktické LékárenstvÃ, 2018, 14, e10-e17.	0.0	2
13	Effectiveness of SmartGuard Technology in the Prevention of Nocturnal Hypoglycemia After Prolonged Physical Activity. Diabetes Technology and Therapeutics, 2017, 19, 299-304.	2.4	12
14	Osteopontin as a discriminating marker for pancreatic cancer and chronic pancreatitis. Cancer Biomarkers, 2016, 17, 55-65.	0.8	21
15	Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study. Diabetes Technology and Therapeutics, 2016, 18, 532-538.	2.4	100
16	Glucose variability, HbA1c and microvascular complications. Reviews in Endocrine and Metabolic Disorders, 2016, 17, 103-110.	2.6	105
17	Effect of glucose variability on pathways associated with glucotoxicity in diabetes: Evaluation of a novel in vitro experimental approach. Diabetes Research and Clinical Practice, 2016, 114, 1-8.	1.1	23
18	Glycemic Variability Is Higher in Type 1 Diabetes Patients with Microvascular Complications Irrespective of Glycemic Control. Diabetes Technology and Therapeutics, 2014, 16, 198-203.	2.4	96

#	Article	IF	CITATIONS
19	Skin Autofluorescence Relates to Soluble Receptor for Advanced Glycation End-Products and Albuminuria in Diabetes Mellitus. Journal of Diabetes Research, 2013, 2013, 1-7.	1.0	17
20	Acute Hyperglycemia Does Not Impair Microvascular Reactivity and Endothelial Function during Hyperinsulinemic Isoglycemic and Hyperglycemic Clamp in Type 1 Diabetic Patients. Experimental Diabetes Research, 2012, 2012, 1-8.	3.8	4